What is the Alosetron REMS Program?

    1. A REMS (Risk Evaluation and Mitigation Strategy) is a program required by the Food and Drug Administration (FDA) to manage known or potential serious risks associated with a drug product. The FDA has determined that a REMS is necessary for alosetron to ensure the benefits of the drug outweigh the risk of serious gastrointestinal (GI) adverse reactions.
    2. The Alosetron REMS Program was implemented to help reduce the risks of a serious GI adverse event.
Only patients who are counseled on the safe use of alosetron by their prescriber should be prescribed alosetron.
Only prescribers who train in the Alosetron REMS Program, based on their understanding of the benefits and risks, should prescribe alosetron.

If you are an alosetron prescriber, you can begin the training by clicking the button below.